Loading
Cancer Cells and Metastasis / Immune Cells in Cancer · Journal article
Nature Cancer · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic study linking commensal fungus Nakaseomyces glabratus enrichment to castration-resistant prostate cancer progression in mice and correlating it with poor survival in patients. The work proposes a gut-to-tumor translocation pathway and identifies an intestinal hydrogel intervention in mice, but provides no clinical trial evidence or patient-level efficacy data.
Observational correlative study in patients combined with experimental mechanistic study in mouse models. Patients with castration-resistant prostate cancer; castrated mice. Intervention: Oral administration of N. glabratus to castrated mice; intestinal hydrogel treatment in mice. Compared with: Control mice (comparator details not specified in abstract).
N. glabratus is enriched in fecal, blood, and tumor samples of castration-resistant prostate cancer patients and correlates with poor overall survival. Oral administration of N. glabratus accelerated cancer progression in castrated mice by promoting PMN-MDSCs infiltration and activation. Androgen deprivation therapy increases intestinal permeability, allowing N. glabratus leakage from gut to tumor via Dectin-2 receptor activation.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This hypothesis-generating study does not provide clinical guidance. It raises questions about fungal dysbiosis in treatment-resistant prostate cancer and suggests potential therapeutic targets, but substantial further clinical work is needed before any intervention can be recommended in patients.
Mechanistic discovery in animal models with correlative human data; no clinical trial evidence, no intervention tested in patients, and no hard clinical outcomes reported.
As stated by the source record.
This hypothesis-generating study does not provide clinical guidance. It raises questions about fungal dysbiosis in treatment-resistant prostate cancer and suggests potential therapeutic targets, but substantial further clinical work is needed before any intervention can be recommended in patients.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Recent studies demonstrate that the gut mycobiota plays a key role in several tumors. However, the contribution of commensal fungi to prostate cancer initiation and progression remains understudied. Here we find that Nakaseomyces glabratus is enriched in fecal, blood and tumor samples of patients with castration-resistant prostate cancer, correlating with patients’ poor overall survival. Oral administration of N. glabratus to castrated mice accelerated cancer progression by promoting infiltration and activation of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Mechanistically, androgen deprivation therapy increases intestinal permeability, resulting in the leakage of N. glabratus from the gut to the tumor site, activating PMN-MDSCs via the Dectin-2 receptor. Treatment of mice with a negatively charged intestinal hydrogel blocks N. glabratus translocation to tumor, reducing PMN-MDSCs’ intratumoral infiltration and activation. Taken together, these findings reveal that the gut-to-tumor translocation of N. glabratus contributes to endocrine resistance in prostate cancer by enhancing the immunosuppressive microenvironment of these tumors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.